Loading
Adding the blood-vessel blocker bevacizumab to first-line chemotherapy delayed relapse by a few months but did not extend life overall.
GOG-0218 (1,873 patients): PFS 14.1 vs 10.3 months with concurrent-plus-maintenance bevacizumab (HR 0.72); no OS benefit (NEJM 2011). ICON7 (1,528): modest PFS gain, with an OS benefit confined to high-risk (stage IV or suboptimally debulked) disease. Bevacizumab became a first-line option, mainly for high-risk patients and as the partner for olaparib in PAOLA-1.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Paclitaxel / nab-paclitaxel.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares MRC Clinical Trials Unit at UCL, Platinum-sensitive ovarian cancer, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, VEGF / VEGFR, Bevacizumab, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.